Medtronic (MDT) announced that it has entered into a distribution agreement with Merit Medical Systems (MMSI), to offer FDA-cleared ViaVerte, a minimally invasive and implant free basivertebral nerve ablation system. It is the first and only BVNA system with a physician-controlled steerable mechanism for precise basivertebral nerve targeting for treating chronic vertebrogenic lower back pain. This agreement continues Medtronic’s momentum in executing on strategic deals that strengthen the company’s leadership within its core franchises and expands an ongoing relationship between Medtronic and Merit.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic gets FDA approval for expanded indication for OmniaSecure
- Private Markets: Kraken pauses IPO plans, Quince raises $500M
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Medtronic put volume heavy and directionally bearish
- Private Markets: Mind Robotics, Nexthop AI land $500M rounds